VedaBio Partners With Mammoth Biosciences to Expand CRISPR-Based Diagnostic Technologies
Posted on 16 Sep 2025
VedaBio (San Diego, CA, USA) has entered into a non-exclusive license agreement with Mammoth Biosciences (Brisbane, CA, USA) for the use of select CRISPR-based technologies in diagnostic applications.
VedaBio harnesses cutting-edge CRISPR technology to deliver rapid, accurate, and accessible diagnostics. The company is dedicated to advancing the next generation of molecular diagnostics to improve healthcare outcomes. Mammoth Biosciences focuses on leveraging its proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-threatening and debilitating diseases.
The agreement provides VedaBio with access to foundational CRISPR intellectual property, enabling the company to accelerate development of purpose-built diagnostic solutions. This alliance reinforces VedaBio’s commitment to building a next-generation platform designed for speed and accuracy, with an initial focus on decentralized healthcare settings. The company’s ultracompact systems are designed to be more specific and enable in vivo gene editing in difficult-to-reach tissues, utilizing both nuclease applications and new editing modalities beyond double-stranded breaks, including base editing, reverse transcriptase editing, and epigenetic editing.
CRISPR-based detection allows for highly specific molecular recognition. When integrated with VedaBio’s platform, it opens the door to rapid, accurate diagnostics that can be deployed in urgent care, outpatient clinics, and other decentralized settings, without sacrificing sensitivity or specificity. With this partnership, VedaBio is uniquely positioned to lead the next wave of CRISPR-powered diagnostics, delivering solutions that are faster, more cost-effective, and better aligned with the realities of today’s healthcare landscape.
“We’re thrilled to work with the Mammoth team to help bring the full promise of CRISPR-based diagnostics to market,” said Frederic Sweeney, PhD, President and CEO of VedaBio. “This initiative expands the avenues for our proprietary platform and allows us to develop highly targeted, amplification-free molecular tests designed for real-world clinical needs.”
“Mammoth’s vision for diagnostics is to enable new solutions that have high impact on patient care,” added Janice Chen, PhD, Co-founder and CTO of Mammoth Biosciences. “The combination of Mammoth’s deep CRISPR intellectual property with VedaBio’s unique approach and product vision is an opportunity to deliver on the potential of CRISPR-based diagnostics.”
Related Links:
VedaBio
Mammoth Biosciences
